A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
Public ClinicalTrials.gov record NCT04688164. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder (The RELIANCE-I Study)
Study identification
- NCT ID
- NCT04688164
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Relmada Therapeutics, Inc.
- Industry
- Enrollment
- 227 participants
Conditions and interventions
Conditions
Interventions
- REL-1017 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 7, 2021
- Primary completion
- Oct 31, 2022
- Completion
- Nov 9, 2022
- Last update posted
- Aug 26, 2024
2021 – 2022
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Relmada Site | Miami | Florida | 33175 | — |
| Relmada Site | Miami Springs | Florida | 33166 | — |
| Relmada Site | Palm Bay | Florida | 32905 | — |
| Relmada Site | Decatur | Georgia | 30030 | — |
| Relmada Site | Chicago | Illinois | 60634 | — |
| Relmada Site | Boston | Massachusetts | 02116 | — |
| Relmada Site | Watertown | Massachusetts | 02472 | — |
| Relmada Site | O'Fallon | Missouri | 63368 | — |
| Relmada Site | New York | New York | 10128 | — |
| Relmada Site | Cincinnati | Ohio | 45215 | — |
| Relmada Site | Austin | Texas | 78737 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04688164, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 26, 2024 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04688164 live on ClinicalTrials.gov.